Form 8-K - Current report:
SEC Accession No. 0001493152-24-051090
Filing Date
2024-12-20
Accepted
2024-12-20 17:00:32
Documents
15
Period of Report
2024-12-16
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45655
2 ex16-1.htm EX-16.1 5885
3 ex16-1_001.jpg GRAPHIC 17851
  Complete submission text file 0001493152-24-051090.txt   256123

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE telo-20241216.xsd EX-101.SCH 3030
5 XBRL LABEL FILE telo-20241216_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE telo-20241216_pre.xml EX-101.PRE 24175
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3795
Mailing Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131
Business Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 786-396-6723
Telomir Pharmaceuticals, Inc. (Filer) CIK: 0001971532 (see all company filings)

EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41952 | Film No.: 241568751
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)